Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 2
Sponsor overview
Gynecologic Oncology Group
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00081263 | https://clinicaltrials.gov/study/NCT00857545 | https://clinicaltrials.gov/study/NCT03077841 | https://clinicaltrials.gov/study/NCT01012817 | https://clinicaltrials.gov/study/NCT03278106 | https://clinicaltrials.gov/study/NCT03534180 | https://clinicaltrials.gov/study/NCT02210858 | https://clinicaltrials.gov/study/NCT02243579 | https://clinicaltrials.gov/study/NCT02520141 | https://clinicaltrials.gov/study/NCT01979523 | https://clinicaltrials.gov/study/NCT02743364 | https://clinicaltrials.gov/study/NCT03601806 | https://clinicaltrials.gov/study/NCT00033644 | https://clinicaltrials.gov/study/NCT00266110
Assets
Linked programs
- Celecoxib: Low Signal (1/5)
- Laboratory Biomarker Analysis: Registry Stop Signal (5/5)
- sargramostim: Registry Stop Signal (3/5)